Skip to content
Bored Studies
RecruitingPhase 2

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Alveus Therapeutics, Inc. · NCT07837973

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
220
US sites recruiting
20
Study start
August 10, 2026
Record last updated
October 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.

Being studied: ALV-100; Placebo

Conditions: Overweight , Obesity; Adults

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key inclusion criteria

  • Adult male and female participants, aged ≥18 to ≤75
  • BMI ≥23 kg/m2 at screening.
  • Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening.
  • Tolerating incretin-based therapy at the discretion of the investigator
  • WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening.
  • Willing to maintain their current general diet and physical activity regimen throughout the study.

Key exclusion criteria

  • Lifetime history of Type 1 or Type 2 diabetes
  • Prior obesity treatment with surgery or a weight loss device.
  • Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity.
  • Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain.
  • Family or personal history of MTC or MEN 2
  • Presence or history of malignant neoplasms within the past 5 years prior to screening

Recruiting US locations

  • University of Alabama - Birmingham

    Birmingham, AL 35294

    Site contact: Shruti Sukhanandi · 205-934-4980 · sbsukhan@uab.edu

  • DM Clinical Research

    Sun City, AZ 85373

    Site contact: Katrina Spencer, MD · 602-325-1553 · Katrina.Spencer@dmclinical.com

  • AMR Clinical

    Tempe, AZ 85281

    Site contact: Sandy Quintanilla · 602-910-3343 · sandy.quintanilla@amr-clinical.com

  • Profound Research

    Oceanside, CA 92058

    Site contact: Christina Spencer · 760-826-2020 · Christina.Spencer@profoundresearch.com

  • DM Clinical Research

    Bradenton, FL 34209

    Site contact: Principal Investigator · 407-508-8249 · jeremy.mcconnell@dmclinical.com

  • DM Clinical Research

    Doral, FL 33166

    Site contact: Principal Investigator · 786-789-1036 · noreen.shaaban@dmclinical.com

  • Clinical Neuroscience Solutions

    Orlando, FL 32801

    Site contact: Marla Graddic · 407-425-5100 · marla.graddic@cnshealthcare.com

  • North Georgia Clinical Research

    Woodstock, GA 30189

    Site contact: Principal Investigator · 678-494-5735 · bram.wieskopf@ngclinicalresearch.com

  • Christie Clinic

    Champaign, IL 61822

    Site contact: Sarah Berlatsky · 217-366-4003 · slberlatsky@christieclinic.com

  • BRCR Global Louisiana

    Gretna, LA 70053

    Site contact: Fernando Del Angel · 561-447-0614 · fdelangel@brcrglobal.com

  • Profound Research

    Farmington Hills, MI 48334

    Site contact: Recruitment Lead · 248-282-3640 · recruitmentleads@profoundresearch.com

  • ALSA Research-Manhattan

    New York, NY 10016

    Site contact: ALSA Research-Manhattan · 646-395-8175 · sstein@alsaresearch.com

  • TMA Headlands

    Wilmington, NC 28403

    Site contact: Megan Crouch · 910-406-2268 · megan.crouch@headlandsresearch.com

  • Lynn Health Science Institute

    Oklahoma City, OK 73106

    Site contact: Lacey Dietz · 405-602-3939 · ldietz@lhsi.net

  • AMR Clinical

    Nashville, TN 37203

    Site contact: John Viselli · 615-334-9150 · john.viselli@amr-clinical.com

  • DM Clinical Research

    Irving, TX 75063

    Site contact: Steven Galvan · 214-304-7491 · steven.galvan@dmclinical.com

  • DM Clinical Research - Dominion Family Healthcare

    San Antonio, TX 78257

    Site contact: Principal Investigator · 830-283-7997 · rashid.atique@dmclinical.com

  • Tekton Research

    San Antonio, TX 78258

    Site contact: Jillian Reynolds · 210-996-2600 · jillian.reynolds@tektonresearch.com

  • DM Clinical Research

    Tomball, TX 77375

    Site contact: Lyannah Contreras · 346-426-8749 · Lyannah.Contreras@dmclinical.com

  • AMR Clinical

    South Jordan, UT 84095

    Site contact: Kate Aragundi · 801-500-3399 · Kate.aragundi@amr-clinical.com

Study contacts (from the official record)

  • Study Director · +1 215-607-2243 · clinicaltrials@alveustx.com
All weight loss studies in Alabama →
Study to Assess the Effect and Safety of ALV-100 on Maintenance of… (NCT07837973) | Bored Studies